Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme shingles vaccine shows efficacy in trial

Merck Sharpe and Dohme shingles vaccine shows efficacy in trial

22nd October 2010

Merck Sharpe and Dohme has reported data from a clinical study that demonstrates the effectiveness of its shingles vaccine Zostavax.

The company conducted a year-long trial which evaluated the drug compared to placebo among 22,439 adults aged between 50 and 59 years.

It was found that during the trial period, 30 cases of shingles occurred among those administered with the vaccine, compared to 99 cases among the control group – a reduction of nearly 70 per cent.

This data will help to support Merck Sharpe and Dohme's efforts to attain regulatory approval for the treatment among patients in the specified age group.

Dr Myron Levin, professor at the University of Colorado School of Medicine and one of the study's investigators, said: "Zostavax significantly reduced the incidence of shingles in adults in their 50s when compared with placebo."

Last month, the company was granted regulatory clearance in the EU to market Sycrest as an effective treatment for manic episodes among bipolar I disorder sufferers.ADNFCR-8000103-ID-800136596-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.